###begin article-title 0
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF7L2</italic>
Genetic Variants of Wnt Transcription Factor TCF-4 (TCF7L2) Putative Promoter Region Are Associated with Small Intestinal Crohn's Disease
###end article-title 0
###begin p 1
Conceived and designed the experiments: MJK IK MC ES WR GW PR SV RC KF DJ CB MS EFS JW. Performed the experiments: MJK IK GW. Analyzed the data: MJK IK MC ES WR GW JB AT LPB SW DJ MS EFS JW. Contributed reagents/materials/analysis tools: ES WR AT KRH PR SV RC KF DJ MS JW. Wrote the paper: MJK JB CB JW.
###end p 1
###begin p 2
###xml 465 470 461 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 535 540 531 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 1649 1654 1645 1650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 65 70 <span type="species:ncbi:9606">human</span>
###xml 570 578 <span type="species:ncbi:9606">patients</span>
###xml 778 786 <span type="species:ncbi:9606">patients</span>
###xml 963 971 <span type="species:ncbi:9606">patients</span>
###xml 1048 1056 <span type="species:ncbi:9606">patients</span>
###xml 1065 1073 <span type="species:ncbi:9606">patients</span>
###xml 1111 1119 <span type="species:ncbi:9606">patients</span>
###xml 1400 1408 <span type="species:ncbi:9606">patients</span>
Reduced expression of Paneth cell antimicrobial alpha-defensins, human defensin (HD)-5 and -6, characterizes Crohn's disease (CD) of the ileum. TCF-4 (also named TCF7L2), a Wnt signalling pathway transcription factor, orchestrates Paneth cell differentiation, directly regulates the expression of HD-5 and -6, and was previously associated with the decrease of these antimicrobial peptides in a subset of ileal CD. To investigate a potential genetic association of TCF-4 with ileal CD, we sequenced 2.1 kb of the 5' flanking region of TCF-4 in a small group of ileal CD patients and controls (n = 10 each). We identified eight single nucleotide polymorphisms (SNPs), of which three (rs3814570, rs10885394, rs10885395) were in linkage disequilibrium and found more frequently in patients; one (rs3814570) was thereby located in a predicted regulatory region. We carried out high-throughput analysis of this SNP in three cohorts of inflammatory bowel disease (IBD) patients and controls. Overall 1399 healthy individuals, 785 ulcerative colitis (UC) patients, 225 CD patients with colonic disease only and 784 CD patients with ileal involvement were used to determine frequency distributions. We found an association of rs3814570 with ileal CD but neither with colonic CD or UC, in a combined analysis (allele positivity: OR 1.27, 95% CI 1.07 to 1.52, p = 0.00737), which was the strongest in ileal CD patients with stricturing behaviour (allele frequency: OR 1.32, 95% CI 1.08 to1.62, p = 0.00686) or an additional involvement of the upper GIT (allele frequency: OR 1.38, 95% CI 1.03 to1.84, p = 0.02882). The newly identified genetic association of TCF-4 with ileal CD provides evidence that the decrease in Paneth cell alpha-defensins is a primary factor in disease pathogenesis.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 205 208 205 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Podolsky1">[1]</xref>
###xml 606 609 606 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Podolsky1">[1]</xref>
###xml 610 613 610 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Wehkamp1">[3]</xref>
###xml 949 952 949 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Louis1">[4]</xref>
###xml 953 956 953 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Silverberg1">[6]</xref>
###xml 1146 1149 1146 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Strober1">[2]</xref>
###xml 1300 1303 1296 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Wehkamp2">[7]</xref>
###xml 1304 1308 1300 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Elphick1">[12]</xref>
###xml 1525 1528 1521 1524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Wehkamp2">[7]</xref>
###xml 1529 1533 1525 1529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Elphick1">[12]</xref>
###xml 1636 1639 1632 1635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Wehkamp4">[9]</xref>
###xml 1641 1645 1637 1641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-vanEs1">[13]</xref>
###xml 1870 1873 1866 1869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Wehkamp4">[9]</xref>
###xml 1875 1879 1871 1875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-vanEs1">[13]</xref>
###xml 1846 1851 <span type="species:ncbi:10090">mouse</span>
Inflammatory bowel disease (IBD), a chronic inflammation of the intestine, is commonly classified into ulcerative colitis (UC) and Crohn's disease (CD) on the basis of clinical features and histopathology [1]. Whereas UC is typically restricted to the colon, CD can occur at many sites, predominantly in the small intestinal ileum, the colon, or in both locations. Emerging details of disease pathogenesis support the current concept that ongoing immune activation in IBD is driven by bacterial microbiota, possibly as a result to an attenuated antimicrobial barrier in genetically predisposed individuals [1]-[3]. Both UC and CD have a complex polygenic, multifactorial background, with a coincidence of susceptibility genes and environmental factors involved in pathogenesis. It is likely that different genetically affected factors may explain the various clinical patterns of IBD, especially location of disease in CD, which is stable over time [4]-[6]. Different explanations for disease location, including a central role of small intestinal Paneth cells and other defects in intestinal innate immunity, were the focus of recent discussion [2]. For ileal CD, reduced expression of small intestinal Paneth cell alpha-defensins HD-5 and -6 (DEFA5 and DEFA6) has been described in several cohorts [7]-[12]. The defensin deficiency is proposed to attenuate the antibacterial host defense capacity of the intestinal mucosa, and may initiate and/or perpetuate the chronic inflammation characterizing the disease at this site [7]-[12]. We recently reported one mechanism to explain, in part, the decrease of these antimicrobial peptides [9], [13]: A reduced expression of the Wnt pathway transcription factor TCF-4 (also known as transcription factor 7-like 2), which directly controls Paneth cell defensin expression (HD-5, HD-6, and orthologous mouse cryptdin peptides [9], [13]).
###end p 4
###begin p 5
###xml 143 147 143 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Hayward1">[14]</xref>
###xml 491 495 488 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-vanEs1">[13]</xref>
###xml 671 675 668 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Gregorieff1">[15]</xref>
###xml 765 769 762 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Gregorieff2">[16]</xref>
###xml 771 775 768 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Korinek1">[17]</xref>
###xml 871 875 868 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-vanEs1">[13]</xref>
###xml 877 881 874 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Batlle1">[18]</xref>
###xml 945 949 942 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-vanEs1">[13]</xref>
###xml 1514 1518 1507 1511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2</italic>
###xml 1619 1622 1612 1615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Wehkamp4">[9]</xref>
###xml 1724 1729 1717 1722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 1802 1807 1795 1800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 1878 1883 1871 1876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 1988 1993 1981 1986 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 2551 2555 2544 2548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Welcome1">[19]</xref>
###xml 2556 2560 2549 2553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Fellermann1">[21]</xref>
###xml 1071 1076 <span type="species:ncbi:10090">mouse</span>
###xml 1748 1756 <span type="species:ncbi:9606">patients</span>
###xml 2013 2021 <span type="species:ncbi:9606">patients</span>
###xml 2175 2183 <span type="species:ncbi:9606">patients</span>
###xml 2361 2369 <span type="species:ncbi:9606">patients</span>
Wnt proteins are a family of secreted morphogenes that play an important role in regulating cell fate and differentiation during embryogenesis [14]. The Wnt signalling pathway is induced by binding of Wnt family proteins to cell surface receptors, leading to stabilization of cytoplasmatic beta-catenin, translocation of this regulatory protein into the nucleus, formation of a complex with transcription factors of the Tcf/Lef family and subsequently the activation of various target genes [13]. In the small intestine, epithelial cells transit through differentiation steps initiated in progenitor cells, which reside adjacent to Paneth cells at the base of the crypts [15]. Wnt signalling helps to maintain an undifferentiated state of the intestinal stem cells [16], [17] and, paradoxically, also regulates positioning, differentiation and maturation of Paneth cells [13], [18]. The Paneth cell gene program is critically dependent on TCF-4 [13]. Using a rodent model, we observed that very small changes (a 50% decrease of TCF-4 levels) are sufficient to compromise mouse Paneth cell cryptidin expression as well as its corresponding antimicrobial function against several bacterial species. We also reported that a reduced level of TCF-4 expression and activity was associated with a decrease of Paneth cell alpha-defensin levels in CD of the small intestine. The decrease of TCF-4 expression was found to be independent of inflammation in the tissue specimens, and also independent of the 1007fsinsC SNP in NOD2, a mutation in this pattern recognition receptor which has previously been associated with ileal CD [9]. We hypothesized that decreased TCF-4 expression might be the result of primary genetic variances in TCF-4, at least in some patients with ileal CD. Since there was a decrease in TCF-4 mRNA levels in these studies, an aberration in the promoter region of TCF-4 could be a possible explanation. Thus, the aim of this study was to sequence the promoter region of the TCF-4 gene in a group of patients with ileal CD to identify potential polymorphisms and to perform a subsequent association study on candidate genetic variants in well-defined cohorts of patients. We identified a total of 8 SNP variants, of which three (rs3814570, rs10885394, rs10885395) were in linkage disequilibrium and seemed to exhibit a higher frequency in ileal CD patients. One of these SNPs was found to be located in a putative regulatory region. We carried out high- throughput analysis of this SNP in three IBD cohorts from Oxford, Leuven and Vienna [19]-[21]. Herein we report an association of the SNP rs3814570 with ileal involvement of CD, but not with colonic CD or UC.
###end p 5
###begin title 6
Methods
###end title 6
###begin title 7
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 13 18 <span type="species:ncbi:9606">human</span>
Patients and human material
###end title 7
###begin p 8
###xml 460 461 460 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</italic>
###xml 658 659 658 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</italic>
###xml 1018 1022 1018 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Welcome1">[19]</xref>
###xml 1023 1027 1023 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Fellermann1">[21]</xref>
###xml 1113 1120 1113 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004496-t001">Table 1</xref>
###xml 1171 1178 1171 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004496-t002">Table 2</xref>
###xml 1324 1331 1324 1331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004496-t003">Table 3</xref>
###xml 53 60 <span type="species:ncbi:9606">patient</span>
###xml 606 614 <span type="species:ncbi:9606">patients</span>
###xml 844 852 <span type="species:ncbi:9606">patients</span>
###xml 866 874 <span type="species:ncbi:9606">patients</span>
###xml 920 928 <span type="species:ncbi:9606">patients</span>
###xml 1044 1051 <span type="species:ncbi:9606">patient</span>
###xml 1249 1257 <span type="species:ncbi:9606">patients</span>
###xml 1639 1647 <span type="species:ncbi:9606">patients</span>
###xml 1934 1942 <span type="species:ncbi:9606">patients</span>
For genetic analysis, we obtained DNA samples from a patient cohort of Caucasians with Crohn's disease (N = 259) or ulcerative colitis (N = 149) from the University Hospital in Vienna, as well as a control group of unrelated, healthy Caucasian blood donors in Stuttgart (N = 833). For subsequent testing, we obtained DNA samples from Caucasians with Crohn's disease (N = 277), UC (N = 74) and healthy controls (N = 242) from the University of Leuven, Belgium (3) as well as an additional third Caucasian cohort from Oxford with DNA of Caucasian healthy individuals (N = 324), UC (N = 562) and CD (N = 473) patients. In line with the Montreal classification (4) three subgroups were defined: ileal disease only (L1), colonic disease only (L2) and ileo colonic disease (L3). A total of 1399 randomly recruited healthy control individuals, 785 UC patients, 225 CD (L2) patients with disease limited to the colon and 784 CD patients with ileal involvement (L1+L3) were used to elucidate the frequency distribution of SNPs [19]-[21]. The numbers of patient subgroups and controls in the different cohorts are shown in Table 1 and detailed statistical analyses are provided in Table 2. To exclude major differences between the groups in age or gender, CD patients as well as controls were sub grouped according to these criteria (Table 3). Additional points of interest were the behaviour as well as the aggressiveness of the disease. We therefore decided to separately test for an association with inflammatory, stricturing and penetrating behaviour as well as an association of the variant with surgery for Crohn's disease. Finally we checked patients with an additional involvement of the upper gastrointestinal tract (L4). The study was approved by the ethics committees of the Medical University Vienna, Austria, the University Hospital Tubingen, Germany, the University of Leuven, Belgium and the Oxford Radcliffe Hospital Trust. All patients gave informed and written consent for their DNA to be analyzed for this study.
###end p 8
###begin title 9
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Overview of the origin of samples from IBD patients and healthy controls.
###end title 9
###begin p 10
healthy blood donors from Stuttgart.
###end p 10
###begin title 11
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 7 13 7 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF7L2</italic>
TCF-4 (TCF7L2) rs3814570 frequency distribution and statistical analysis of combined cohort samples.
###end title 11
###begin p 12
C<>T allele frequency difference.
###end p 12
###begin p 13
CC<>CT+TT allele positivity; frequent homo vs heterozygous and rare homozygous.
###end p 13
###begin p 14
###xml 448 456 <span type="species:ncbi:9606">patients</span>
The different distribution of genotypes is demonstrated for each group and subgroup: controls, inflammatory bowel disease (IBD), Crohn's disease (CD), ulcerative colitis (UC), CD with solely colonic involvement (L2) and CD with solely ileal (L1) as well as ileal and colonic involvement (L3). Differences in genotype distribution compared to controls in general as well as the amount of all carriers (allele positivity) were subject to t- tests in patients with UC, CD and the CD subgroups L2 as well as L1+L3. Finally, results of the Armitage's trend tests for verification of significant associations of the rare T- variant are shown.
###end p 14
###begin title 15
###xml 125 130 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 132 138 132 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF7L2</italic>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 393 401 <span type="species:ncbi:9606">patients</span>
Patients and controls sub grouped according to age and gender. Shown are percentages of individuals per group as well as the TCF-4 (TCF7L2) rs3814570 T- allele frequency (minor allele frequency MAF). Differences in genotype distribution compared to controls in general as well as the amount of all carriers (allele positivity) and the amount of homozygous carriers were subject to t- tests in patients with ileal CD. Finally, results of the Armitage's trend tests for verification of significant associations of the rare T- variant are shown.
###end title 15
###begin p 16
MAF = minor allele frequency.
###end p 16
###begin p 17
controls A1 only from Leuven.
###end p 17
###begin title 18
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
Sequencing of TCF-4 promoter and gene region
###end title 18
###begin p 19
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 230 235 230 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 323 327 323 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Duval1">[22]</xref>
###xml 372 377 372 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
To determine possible genetic variants in the TCF-4 promoter, we sequenced the 2.1 kb upstream region of randomly selected healthy controls (n = 10) and patients with ileal CD (n = 10). In addition, we sequenced the region of the TCF-4 gene in which functional insertions and deletions have been reported in colonic cancer [22]. Subsequently, a sequence analysis of known TCF-4 exons was carried out, including approximately100 bp intron boundaries, to identify additional potential variants of this gene in these regions. Primers were designed using ENSG00000148737 of the Ensemble genome browser database for the promoter and exon sequencing. Sequencing was performed according to standard procedures and the primers are provided upon request.
###end p 19
###begin title 20
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
TCF-4 genotyping
###end title 20
###begin p 21
###xml 431 436 431 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
Leukocyte DNA was isolated by standard procedures (QIAamp DNA Blood Mini Kit, Qiagen, Hilden, Germany) from whole blood samples. Genotyping of the samples from the cohorts from Vienna and Leuven was performed using the matrix assisted laser desorption/ionization time-of-flight (MALDI-TOF) based mass spectrometry (MS) of allele specific primer extension products with a system from Bruker (Daltonik,Leipzig, Germany). Presence of TCF-4 SNPs detected by MALDI-TOF MS was confirmed by TaqMan(R) analysis and direct sequencing in a subset of samples. MALDI-TOF MS based genotyping of the DNA samples obtained from Oxford was carried out using a MassARRAY(R) Compact System from Sequenom (San Diego, USA). Primers were designed using reference sequence NT 030059 and will be provided on request.
###end p 21
###begin title 22
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2</italic>
NOD2 genotype analysis
###end title 22
###begin p 23
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2</italic>
###xml 209 212 209 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Wehkamp2">[7]</xref>
###xml 93 100 <span type="species:ncbi:9606">patient</span>
Genotyping for the common NOD2 variants (SNP8, SNP12, and SNP13) was performed in the Vienna patient samples using TaqMan technology (Applied Biosystems, Foster City, California, USA), as described previously [7].
###end p 23
###begin title 24
Computer analysis and statistics
###end title 24
###begin p 25
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In silico</italic>
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 717 718 717 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 831 836 831 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
In silico screen of a 10 kb TCF-4 upstream region was performed using "Promoter 2.0: for the recognition of PolII promoter sequences." TESS (Transcription Element Search System) database software allowed assessing of potential binding sites for certain transcription factors in the candidate sequence. Polymorphisms were tested for Hardy-Weinberg equilibrium using Finetti specialized software () using log likelihood ratio chi square test in the three cohorts. For genetic analysis (comparing IBD subgroups versus controls) we used this software to calculate odds ratios, Confidence Intervals (C.I.) and to perform Pearson's goodness-of-fit chi-square tests. Differences in genotype frequencies were subject to both t tests and Armitage's trend tests. Values below 0.05 were considered significant. Linkage disequilibrium between TCF-4 SNPs and haplotype blocks were calculated and identified using Haploview. To exclude a coincidental association of the SNP rs3814570, the significance of p- values<0.05 was verified using Benjamini- Hochberg correction in the overall group.
###end p 25
###begin title 26
Results
###end title 26
###begin title 27
SNP selection and haplotypes
###end title 27
###begin p 28
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 134 139 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 261 269 261 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004496-g001">Figure 1</xref>
###xml 780 789 780 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004496-g002">Figure 2a</xref>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
###xml 371 378 <span type="species:ncbi:9606">patient</span>
###xml 469 477 <span type="species:ncbi:9606">patients</span>
###xml 616 624 <span type="species:ncbi:9606">patients</span>
To investigate potential genetic linkage of TCF-4 to ileal CD, we screened for SNPs by sequencing 2.1 kb of the 5' flanking region of TCF-4 in a random group of 10 ileal CD patients and 10 healthy controls. We found eight SNPs in this putative promoter region (Figure 1), of which three (rs3814570, rs10885394, rs10885395) were in linkage disequilibrium (LD) in both the patient and control groups. In the control group, two of ten individuals carried the variants; in patients with ileal CD, six of ten individuals were heterozygous for the SNPs. On the basis of these findings, we studied a well-defined cohort of patients with CD and healthy controls from Vienna, Austria. In both the control and CD groups, we found LD between the 3 SNPs that defined a novel haplotype block (Figure 2a).
###end p 28
###begin title 29
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF7L2</italic>
Sequencing of TCF-4 (TCF7L2) 5'upstream putative promoter region.
###end title 29
###begin p 30
###xml 83 91 <span type="species:ncbi:9606">patients</span>
###xml 434 442 <span type="species:ncbi:9606">patients</span>
Sequencing of a 2.1 kb upstream region was performed in 10 healthy controls and 10 patients with ileal Crohn's disease. Putative regulatory regions were determined using promoter prediction software. Likely and marginal prediction sites are depicted as red boxes (upper panel). Relative location of identified variants is marked via grey dashes (upper part) and their allele frequency is demonstrated via bars for controls as well as patients (lower part).
###end p 30
###begin title 31
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF7L2</italic>
Distribution of haploblocks of TCF-4 (TCF7L2).
###end title 31
###begin p 32
###xml 151 156 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 158 164 158 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF7L2</italic>
###xml 320 321 320 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 332 342 332 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004496-g002">Figure 2b:</xref>
###xml 413 418 413 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 420 426 420 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF7L2</italic>
###xml 518 519 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 519 520 519 520 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Both colour schemes (a and b) illustrate the linkage disequilibria. The variants are listed in the upper part of a and b, respectively. Haplotypes for TCF-4 (TCF7L2) rs3814570 (SNP1), rs10885394 (SNP2), rs10885395 (SNP3) and SNPs associated with diabetes in the Vienna cohort are shown in a. A missing number for D' or r2 equals 1. Figure 2b: HapMap data based haplotype blocks and linkage disequilibria (LD) for TCF-4 (TCF7L2) polymorphisms. The intensity of red colouring in b is proportional to the extent of D' or r2 respectively and a missing number for each of them equals. The observed SNP in the putative promoter region is not part of any significant haplotype block.
###end p 32
###begin p 33
###xml 3 12 3 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in silico</italic>
###xml 220 225 220 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 613 618 613 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 852 861 840 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004496.s001">Figure S1</xref>
###xml 1036 1041 1024 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 1105 1114 1093 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004496-g002">Figure 2b</xref>
###xml 285 293 <span type="species:ncbi:9606">patients</span>
###xml 793 801 <span type="species:ncbi:9606">patients</span>
An in silico promoter and transcription factor binding-site analysis of the sequenced region revealed a potential regulatory region close to the location of rs3814570. Because of (i) the observed decreased expression of TCF-4 mRNA, (ii) the higher frequency of the promoter variant in patients as well as (iii) the presence of a putative regulatory locus, we tested the hypothesis that rs3814570 exhibits an association with small intestinal involvement of CD. To exclude additional major variants in the gene region and possible LD of the identified promoter SNPs to other potentially functional variants in the TCF-4 gene, we sequenced known coding exons, with approximately100 kb overlapping intron boundaries in 10 randomly chosen controls (6 identical to promoter analysis) as well as 25 patients with ileal CD (7 identical to promoter analysis) (Figure S1). We found ten additional putative SNPs, of which two were in LD, but none exhibited LD with the described promoter SNPs (data not shown). A further search for haplotypes in TCF-4 was conducted based on published data from the HapMap project (Figure 2b), and no haplotype block including rs3814570 or additional SNPs in the gene region were identified.
###end p 33
###begin title 34
###xml 2 7 2 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
A TCF-4 promoter variant is associated with ileal CD predisposition
###end title 34
###begin p 35
###xml 554 561 554 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004496-t002">Table 2</xref>
###xml 1217 1225 1217 1225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004496-g003">Figure 3</xref>
###xml 131 139 <span type="species:ncbi:9606">patients</span>
###xml 178 186 <span type="species:ncbi:9606">patients</span>
###xml 252 260 <span type="species:ncbi:9606">patients</span>
###xml 416 424 <span type="species:ncbi:9606">patients</span>
Analysis of SNP rs3814570 frequency distribution was carried out in a total of 1399 controls (T allele frequency = 25.59%), 785 UC patients (T allele frequency = 25.22%), 225 CD patients with L2 classification (T allele frequency = 24.67%), and 784 CD patients with ileal involvement (L1+L3) (T allele frequency = 29.66%). In contrast to UC (OR 0.98, 95% CI 0.85 to 1.13, n.s.) which was similar to controls, the CD patients in aggregate exhibited a weak association for the minor variant (T allele positivity: OR 1.18, 95% CI 1.01 to1.39, p = 0.04358) (Table 2). Consistent with our initial hypothesis, investigation of the different CD subgroups revealed an association of the variant (T) with ileal CD (OR 1.23, 95% CI 1.07 to 1.41, p = 0.00371), but not with colonic CD (OR 0.95, 95% CI 0.76 to 1.20, ns). Testing for allele positivity by analyzing wildtype homozygous individuals (CC) versus all carriers of the minor variant (CT+TT), revealed the effect more clearly comparing healthy controls versus ileal CD (OR 1.27, 95% CI 1.07-1.52, p = 0.007372). Odds ratios and confidence intervals of the group analysis' in the respective cohorts as well as the combined analysis of all genotyping results are shown in Figure 3.
###end p 35
###begin title 36
Differences in frequency distribution of rs3814570 in the different disease subgroups compared to healthy controls.
###end title 36
###begin p 37
###xml 333 341 <span type="species:ncbi:9606">patients</span>
###xml 406 414 <span type="species:ncbi:9606">patients</span>
###xml 478 486 <span type="species:ncbi:9606">patients</span>
Odds ratios and confidence intervals for the different comparisons are shown. The frequency distribution of rs3814570 was analyzed in different cohorts and combined samples: odds ratios and 95% confidence interval for allele frequency (upper panel) and allele positivity (amount of all T- allele carriers, lower panel) are shown for patients with ulcerative colitis (UC) (left panel), Crohn's disease (CD) patients with solely colonic involvement (L2, middle panel) and finally patients classified as either L1 (solely ileal) or L3 (ileal and colonic involvement) (right panel) compared to healthy control individuals.
###end p 37
###begin p 38
###xml 72 81 72 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004496.s002">Tables S1</xref>
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004496.s003">S2</xref>
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004496.s004">S3</xref>
###xml 1297 1304 1297 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004496-t002">Table 2</xref>
###xml 348 356 <span type="species:ncbi:9606">patients</span>
###xml 504 512 <span type="species:ncbi:9606">patients</span>
###xml 1093 1101 <span type="species:ncbi:9606">patients</span>
Since there were differences in allele frequencies between the cohorts (Tables S1, S2, and S3), we tested if those apparent frequency differences were statistically significant. In general the Oxford cohort exhibited a lower T allele frequency in controls (23.30%) compared to Leuven (26.65%) as well as to Vienna (26.17%) The same was true for CD patients (T allele frequency in Oxford: 27.38%, Leuven: 30.14% and Vienna: 28.96%), but could partly be explained by the different percentage of colonic CD patients in the groups. For CD with ileal involvement only, the frequency distributions in the cohorts were more similar (T allele frequency in Oxford: 28.30%, Leuven: 30.82% and Vienna: 30.64%) and not significantly different. Even though we found a possible change in frequency distribution between the Oxford control group with both the Leuven (allele frequency: OR 1.20, 95% CI 0.91 to 1.57, p = 0.19618) and Vienna controls (allele frequency: OR 1.17, 95% CI 0.94 to 1.44, p = 0.15453), the differences did not achieve statistical significance. The elevated SNP frequency in ileal CD patients was seen in three independent European cohorts, and a distinct significant association of the minor variant for rs3814570 with ileal CD could be observed in the combined analysis of all samples (Table 2).
###end p 38
###begin title 39
###xml 100 108 <span type="species:ncbi:9606">patients</span>
The association of rs3814570 with ileal CD is independent of gender but slightly more pronounced in patients >40 years
###end title 39
###begin p 40
###xml 154 161 154 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004496-t003">Table 3</xref>
###xml 110 117 <span type="species:ncbi:9606">patient</span>
###xml 229 232 <span type="species:ncbi:9606">men</span>
###xml 237 242 <span type="species:ncbi:9606">women</span>
###xml 265 273 <span type="species:ncbi:9606">patients</span>
###xml 410 418 <span type="species:ncbi:9606">patients</span>
To make sure there is no disarrangement of age as well as gender we subgrouped all controls as well as the CD patient groups according to these criteria (Table 3). There were no consistent differences in allele frequency between men and women in either controls or patients; therefore we exclude a gender specific effect of the variant. Interestingly we found an increased association of the variant comparing patients with ileal, but not solely colonic CD of the age group A3 (>40 years) with controls of the same age group in the overall analysis, as well as in two separate cohorts (Leuven and Oxford). In the overall analysis a statistical significance for homozygous carriers was present (homozygous carriers: OR 2.02, 95% CI 1.01 to 4.05, p = 0.04347)
###end p 40
###begin title 41
###xml 41 49 <span type="species:ncbi:9606">patients</span>
rs3814570 shows the highest frequency in patients with stricturing ileal Cohn's disease
###end title 41
###begin p 42
###xml 116 123 116 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004496-t004">Table 4</xref>
###xml 899 906 899 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004496-t004">Table 4</xref>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 388 396 <span type="species:ncbi:9606">patients</span>
###xml 817 825 <span type="species:ncbi:9606">patients</span>
We grouped the patients according to their behaviour into B1 (inflammatory), B2 (stricturing) and B3 (penetrating) (Table 4). We found the highest frequency in the overall analysis within the ileal CD subgroup with stricturing behaviour (T allele frequency: 31.25%). This was also obvious in 2 separate cohorts (T allele frequency in Oxford: 29.81%, Leuven: 35.83%) but not seen in L2 CD patients. The association of the SNP with stricturing ileal CD compared to healthy controls exhibited a high significance in the overall analysis (allele frequency: OR 1.32, 95% CI 1.08 to1.62, p = 0.00686) and an additionally increased amount of homozygous carriers was observed (homozygous carriers: OR 1.71, 95% 1.11 to 2.63, p = 0.01460). To identify a possible association with aggressiveness of disease we also grouped the patients in such that have had at least one surgery for CD and those who did not (Table 4). No consistent result was observed; even though in two cohorts a trend towards a higher frequency in the ileal CD group with surgery (T allele frequency in Oxford: 28.93% and Leuven: 31.58%) and a significant stronger association with ileal CD in the surgery group compared to controls in one cohort (Oxford allele frequency: OR 1.34, 95% CI 1.03 to 1.74, p = 0.02885) was present.
###end p 42
###begin title 43
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients sub grouped according to disease behaviour, L4 phenotype and surgery.
###end title 43
###begin p 44
MAF = minor allele frequency.
###end p 44
###begin p 45
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 69 75 69 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF7L2</italic>
###xml 214 221 214 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004496-t002">Table 2</xref>
###xml 358 366 <span type="species:ncbi:9606">patients</span>
Shown are percentages of individuals per group as well as the TCF-4 (TCF7L2) rs3814570 T- allele frequency (minor allele frequency MAF). Differences in genotype distribution compared to controls (all controls from Table 2) in general as well as the amount of all carriers (allele positivity) and the amount of homozygous carriers were subject to t- tests in patients with ileal CD. Finally, results of the Armitage's trend tests for verification of significant associations of the rare T- variant are shown.
###end p 45
###begin title 46
###xml 63 71 <span type="species:ncbi:9606">patients</span>
rs3814570 confers to the risk of an additional L4 phenotype in patients with ileal CD
###end title 46
###begin p 47
###xml 84 91 <span type="species:ncbi:9606">patient</span>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 252 260 <span type="species:ncbi:9606">patients</span>
###xml 294 302 <span type="species:ncbi:9606">patients</span>
###xml 309 317 <span type="species:ncbi:9606">patients</span>
###xml 324 332 <span type="species:ncbi:9606">patients</span>
###xml 344 352 <span type="species:ncbi:9606">patients</span>
###xml 386 394 <span type="species:ncbi:9606">patients</span>
###xml 401 409 <span type="species:ncbi:9606">patients</span>
###xml 417 425 <span type="species:ncbi:9606">patients</span>
###xml 437 445 <span type="species:ncbi:9606">patients</span>
###xml 479 487 <span type="species:ncbi:9606">patients</span>
###xml 495 503 <span type="species:ncbi:9606">patients</span>
###xml 511 519 <span type="species:ncbi:9606">patients</span>
###xml 602 610 <span type="species:ncbi:9606">patients</span>
###xml 711 719 <span type="species:ncbi:9606">patients</span>
To specifically address the question of upper GIT involvement (L4) we separated the patient groups in further subgroups according to this specific additional phenotype. In general the amount of patients with upper GIT involvement was quite low: Leuven patients with additional L4 phenotype: 12 patients L3; 4 patients L2; 6 patients L1; Oxford patients with additional L4 phenotype: 36 patients L3; 4 patients L2; 10 patients L1; Vienna patients with additional L4 phenotype: 40 patients L3; 10 patients L2; 11 patients L1. Comparing the allele frequencies with controls, we found a slight increase in patients with ileal CD and additional L4 phenotype (T allele frequency: 32.17%). This did not account for L2 patients with upper GIT involvement. The stronger association of the rare variant was also statistically significant in the overall analysis (allele frequency: OR 1.38, 95% CI 1 1.03 to1.84, p = 0.02882).
###end p 47
###begin title 48
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2</italic>
rs3814570 is independent of NOD2
###end title 48
###begin p 49
###xml 55 59 55 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2</italic>
###xml 252 256 252 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2</italic>
###xml 445 449 441 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2</italic>
###xml 484 488 480 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2</italic>
###xml 559 562 555 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Wehkamp4">[9]</xref>
###xml 640 644 636 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2</italic>
###xml 1151 1155 1147 1151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2</italic>
###xml 1308 1313 1304 1309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 1322 1326 1318 1322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2</italic>
###xml 391 399 <span type="species:ncbi:9606">patients</span>
###xml 465 473 <span type="species:ncbi:9606">patients</span>
###xml 620 628 <span type="species:ncbi:9606">patients</span>
###xml 730 738 <span type="species:ncbi:9606">patients</span>
###xml 778 786 <span type="species:ncbi:9606">patients</span>
###xml 821 829 <span type="species:ncbi:9606">patients</span>
###xml 988 996 <span type="species:ncbi:9606">patients</span>
###xml 1137 1145 <span type="species:ncbi:9606">patients</span>
###xml 1245 1253 <span type="species:ncbi:9606">patients</span>
Given that the 3020insC frameshift mutation (SNP13) in NOD2 is a known susceptibility factor for CD of the ileum and is associated with reduced HD-5 and-6 levels, we investigated if the observed association of rs3814570 with ileal CD is independent of NOD2 in the Vienna and Leuven cohorts. We previously reported that the effects of reduced TCF-4 on Paneth cell alpha-defensins in ileal CD patients were independent of the effects of the SNP13 NOD2 variant, since patients with this NOD2 mutation showed a much more marked decrease of HD-5 and -6 expression [9]. The independence of the factors suggests that excluding patients harbouring NOD2 SNP13 should yield similar allele frequencies of rs3814570 in the remaining ileal CD patients. Indeed, comparing all Leuven ileal CD patients (n = 232) to a subgroup excluding patients harbouring SNP13 (n = 191), there were no differences in allele frequency (OR 0.99) or allele positivity (OR 0.98). The same was true for the Vienna ileal CD patients (n = 204): following SNP13 exclusion (n = 154) the allele frequency gave an OR 1.06 and an allele positivity of OR 1.04. Thus, exclusion of patients with NOD2 frameshift mutation SNP13 does not alter the observed allele frequencies of rs3814570 in patients with ileal CD, supporting independent effects of this TCF-4 SNP and NOD2 SNP13 in ileal CD.
###end p 49
###begin title 50
Discussion
###end title 50
###begin p 51
###xml 113 118 113 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 120 126 120 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF7L2</italic>
###xml 385 392 385 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATG16L1</italic>
###xml 461 463 461 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HM</sup>
###xml 469 473 469 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Cadwell1">[23]</xref>
###xml 615 619 615 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2</italic>
###xml 680 683 680 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Wehkamp2">[7]</xref>
###xml 685 688 685 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Wehkamp3">[8]</xref>
###xml 690 694 690 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Elphick1">[12]</xref>
###xml 764 768 764 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2</italic>
###xml 784 788 784 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Kobayashi1">[24]</xref>
###xml 1057 1060 1057 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Wehkamp2">[7]</xref>
###xml 1062 1065 1062 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Wehkamp3">[8]</xref>
###xml 1067 1071 1067 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Elphick1">[12]</xref>
###xml 1120 1124 1120 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2</italic>
###xml 1366 1370 1366 1370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Hooper1">[25]</xref>
###xml 1372 1376 1372 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Backhed1">[26]</xref>
###xml 1478 1482 1478 1482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Schreiber1">[27]</xref>
###xml 1496 1500 1496 1500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2</italic>
###xml 1673 1676 1673 1676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Wehkamp3">[8]</xref>
###xml 1785 1788 1785 1788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Wehkamp3">[8]</xref>
###xml 1925 1930 1921 1926 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 1980 1983 1976 1979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Wehkamp4">[9]</xref>
###xml 2007 2012 2003 2008 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 2195 2199 2191 2195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HD-5</italic>
###xml 2204 2208 2200 2204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HD-6</italic>
###xml 2221 2226 2217 2222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 2439 2444 2435 2440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 2542 2547 2538 2543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 3143 3148 3139 3144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 3463 3467 3459 3463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2</italic>
###xml 3532 3536 3528 3532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Medici1">[28]</xref>
###xml 3807 3811 3803 3807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Tenesa1">[29]</xref>
###xml 3975 3983 3971 3979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004496-g003">Figure 3</xref>
###xml 334 342 <span type="species:ncbi:9606">patients</span>
###xml 464 468 <span type="species:ncbi:10090">mice</span>
###xml 779 783 <span type="species:ncbi:10090">mice</span>
###xml 1096 1104 <span type="species:ncbi:9606">patients</span>
###xml 1208 1216 <span type="species:ncbi:9606">patients</span>
###xml 1590 1598 <span type="species:ncbi:9606">patients</span>
###xml 2488 2496 <span type="species:ncbi:9606">patients</span>
###xml 2739 2747 <span type="species:ncbi:9606">patients</span>
In a hypothesis driven candidate gene approach, we investigated the association of sequence polymorphisms in the TCF-4 (TCF7L2) promoter with ileal Crohn's disease. The reported findings represent the third identified genetic association with a link to Paneth cells in ileal CD. Recently Cadwell et al. published that Crohn's disease patients homozygous for the disease risk allele of ATG16L1 display Paneth cell abnormalities which were also present in ATG16L1HM mice [23]. Earlier we and others have shown that the 3020insC (SNP13) mutation in the intracellular, in Paneth cell present muramyl dipeptide receptor NOD2, is associated with especially reduced levels of HD5 and -6 [7], [8], [12]. Such a distinct deficiency in the innate defence also characterizes NOD2 knock out mice [24]. The characteristic decrease of HD-5 and -6 in ileal CD results in an impaired innate immunity at the small intestinal barrier which is distinguished by reduced antibacterial activity in the epithelium, and proposed to disrupt the host - microbe balance at the mucosa [7], [8], [12]. It is also apparent in patients with wild type NOD2 or either missense mutations (SNP8 and SNP12) but was, however, more pronounced in patients with the frameshift (SNP13) mutation. Different studies point to a delicate balance between commensal microbes and the intestinal mucosa (for review [25], [26]). We propose that a perturbation in this dynamic interplay has an important role in IBD pathogenesis [27]. In summary, NOD2 SNP13 can in part explain a loss in HD-5 and -6 level but is found in only a minority of patients with ileal CD, but diminished defensin levels are present in the majority [8] and have an immediate effect on antimicrobial activity against and composition of the intestinal microflora [8]. A different functional link in ileal CD leading to diminished Paneth cell alpha-defensins HD-5 and -6, is a reduced mRNA expression of TCF-4, which has been previously reported by our group [9]. The identification of TCF-4 as a new factor in the pathogenesis of ileal CD provides a more general mechanism for the deficit in HD-5 and -6. Since TCF-4 binds to and directly regulates the promoter regions of HD-5 and HD-6, diminished TCF-4 expression, maybe consequent on a genetic mutation, could account for a decrease in both of these defensins. The current data give support to the hypothesis of a genetic association between a rare SNP variant of TCF-4 and ileal involvement in CD in a subset of patients. This variant, the rs3814570 T allele in the TCF-4 promoter region, was most prevalent in CD localized to the ileum and no association with either colonic CD or UC was found. The strongest association with the variant was present in ileal CD patients with stricturing disease behaviour as well as those with an additional involvement of the upper GIT. The fact that genetic variants in TCF-4, a factor indispensable for Paneth cell function, are specifically associated with ileal CD provides further evidence that a decrease in HD-5 and -6 is predisposing and can be seen as a primary defect in the disease. The reported association between the TCF-4 SNP and small intestinal involvement was found in all cohorts from Vienna, Oxford and Leuven. Variability of allele frequencies in controls between the Oxford cohort and the two cohorts from the European mainland might be explained by population differences as a consequence of a heterogenic ethnical history. For NOD2 an even greater heterogeneity among Europeans has been reported [28]. In a letter regarding the frequency variability of DLG5 polymorphisms, another gene reported to exhibit an association with IBD, Tenesa et al. caution against pooling data from different populations, because true but in the cohorts different effects might be concealed [29]. The overall analysis of controls versus ileal CD showed a marginally lower difference when compared with the individual results of the Vienna and Oxford cohorts (Figure 3), so this might play a role in our analysis. However, differences in overall allele frequencies in the control cohorts were not statistically different.
###end p 51
###begin p 52
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 147 152 147 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 199 203 199 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Grant1">[30]</xref>
###xml 353 357 353 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Duval1">[22]</xref>
###xml 501 510 501 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004496-g002">Figure 2a</xref>
###xml 321 329 <span type="species:ncbi:9606">patients</span>
Associations of genetic variations of the TCF-4 gene with other diseases exist, but data are limited. An association of two non-coding SNPs in the TCF-4 gene has been observed with diabetes mellitus [30] and, in another study, an association with deletions and insertions of adenines in the coding region was reported in patients with colorectal cancer [22]. We did not find any genetic association of these polymorphisms in UC nor CD (or in any of the clinical subgroups) in the samples from Vienna (Figure 2a and data not shown for repetitive A polymorphic region).
###end p 52
###begin p 53
###xml 147 151 143 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-Wehkamp5">[31]</xref>
###xml 153 157 149 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004496-George1">[32]</xref>
###xml 198 203 194 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
Given that Wnt/TCF-4 plays a major role in Paneth cell maturation, aside from its direct function in the expression of Paneth cell alpha-defensins [31], [32], the observed link between ileal CD and TCF-4 suggests that impaired cell differentiation might be involved in the disorder. This would differ from many other views on IBD pathogenesis which emphasize the role of dysregulated immune function in otherwise normally functioning cells. If indeed a hypothesis on aberrant cell maturation proves significant, effective new therapeutic strategies might alternatively target steps in differentiation in addition to regulate or influence downstream impaired effector molecules like HD-5 and -6.
###end p 53
###begin title 54
Supporting Information
###end title 54
###begin p 55
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF7L2</italic>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
###xml 414 422 <span type="species:ncbi:9606">patients</span>
Sequencing of TCF-4 (TCF7L2) exon regions and intron boundaries. Sequencing of exon regions was performed in a representative and limited number of healthy controls as well as Crohn's disease patients with known clinical phenotype (small intestinal CD). The relative location of identified variants is marked via grey dashes (upper part) and their allele frequency is demonstrated via bars for controls as well as patients (lower part). P<0,05 is considered statistical significant.
###end p 55
###begin p 56
(10.07 MB DOC)
###end p 56
###begin p 57
Click here for additional data file.
###end p 57
###begin p 58
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 7 13 7 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF7L2</italic>
TCF-4 (TCF7L2) rs3814570 frequency distribution and statistical analysis of Oxford cohort samples. The different distribution of genotypes is demonstrated for each group and subgroup: controls, inflammatory bowel disease (IBD), Crohn's disease (CD), ulcerative colitis (UC), CD with solely colonic involvement (L2) and CD with solely ileal (L1), and ileo-colonic CD (L3). Differences in genotype distribution compared to controls as well as the number of carriers (allele positivity) were subject to t- tests. Results of the Armitage's trend tests for verification of significant associations with the minor T- variant are shown.
###end p 58
###begin p 59
(0.05 MB DOC)
###end p 59
###begin p 60
Click here for additional data file.
###end p 60
###begin p 61
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 7 13 7 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF7L2</italic>
TCF-4 (TCF7L2) rs3814570 frequency distribution and statistical analysis of Vienna cohort samples. The different distribution of genotypes is shown for each group and subgroup: controls, inflammatory bowel disease (IBD), Crohn's disease (CD), ulcerative colitis (UC), CD with solely colonic involvement (L2), CD with solely ileal (L1) and ileo-colonic CD (L3). Differences in genotype distribution compared to controls as well as the number of carriers (allele positivity) were subject to t- tests as well as Armitage's trend test.
###end p 61
###begin p 62
(0.05 MB DOC)
###end p 62
###begin p 63
Click here for additional data file.
###end p 63
###begin p 64
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF-4</italic>
###xml 7 13 7 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCF7L2</italic>
TCF-4 (TCF7L2) rs3814570 frequency distribution and statistical analysis of Leuven cohort samples. The different distribution of genotypes is demonstrated for each group and subgroup: controls, inflammatory bowel disease (IBD), Crohn's disease (CD), ulcerative colitis (UC), CD with solely colonic involvement (L2), CD with solely ileal (L1) and ileo-colonic CD (L3). Differences in genotype distribution compared to controls as well as the number of carriers (allele positivity) were subject to t- tests as well as Armitage's trend test.
###end p 64
###begin p 65
(0.05 MB DOC)
###end p 65
###begin p 66
Click here for additional data file.
###end p 66
###begin p 67
We thank Drs. C. Schaefer, K. Rotfuss, H.P. Kreichgauer and others from the Robert Bosch Hospital for help with sample procurement. We thank K. Siegel, J. Bader and A. Zwicker for excellent technical assistance. We also thank M. Eichelbaum for discussion and support.
###end p 67
###begin title 68
References
###end title 68
###begin article-title 69
Inflammatory bowel disease.
###end article-title 69
###begin article-title 70
Immunology. Unraveling gut inflammation.
###end article-title 70
###begin article-title 71
Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease.
###end article-title 71
###begin article-title 72
Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease.
###end article-title 72
###begin article-title 73
Genotypes and phenotypes in Crohn's disease: do they help in clinical management?
###end article-title 73
###begin article-title 74
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.
###end article-title 74
###begin article-title 75
NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal a-defensin expression.
###end article-title 75
###begin article-title 76
Reduced Paneth cell {alpha}-defensins in ileal Crohn's disease.
###end article-title 76
###begin article-title 77
The Paneth Cell {alpha}-Defensin Deficiency of Ileal Crohn's Disease Is Linked to Wnt/Tcf-4.
###end article-title 77
###begin article-title 78
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Defensin expression in chronic pouchitis in patients with ulcerative colitis or familial adenomatous polyposis coli.
###end article-title 78
###begin article-title 79
###xml 108 113 <span type="species:ncbi:9606">human</span>
NOD2-expressing bone marrow-derived cells appear to regulate epithelial innate immunity of the transplanted human small intestine.
###end article-title 79
###begin article-title 80
###xml 31 36 <span type="species:ncbi:9606">Human</span>
Impaired Luminal Processing of Human Defensin-5 in Crohn's Disease: Persistence in a Complex with Chymotrypsinogen and Trypsin.
###end article-title 80
###begin article-title 81
Wnt signalling induces maturation of Paneth cells in intestinal crypts.
###end article-title 81
###begin article-title 82
Wnt/Notch signalling and information processing during development.
###end article-title 82
###begin article-title 83
Wnt signaling in the intestinal epithelium: from endoderm to cancer.
###end article-title 83
###begin article-title 84
Expression Pattern of Wnt Signaling Components in the Adult Intestine.
###end article-title 84
###begin article-title 85
###xml 73 77 <span type="species:ncbi:10090">mice</span>
Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4.
###end article-title 85
###begin article-title 86
Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB.
###end article-title 86
###begin article-title 87
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.
###end article-title 87
###begin article-title 88
Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis.
###end article-title 88
###begin article-title 89
###xml 50 55 <span type="species:ncbi:9606">human</span>
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon.
###end article-title 89
###begin article-title 90
Frequent frameshift mutations of the TCF-4 gene in colorectal cancers with microsatellite instability.
###end article-title 90
###begin article-title 91
###xml 59 64 <span type="species:ncbi:10090">mouse</span>
###xml 69 74 <span type="species:ncbi:9606">human</span>
A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells.
###end article-title 91
###begin article-title 92
Nod2-Dependent Regulation of Innate and Adaptive Immunity in the Intestinal Tract.
###end article-title 92
###begin article-title 93
Commensal host-bacterial relationships in the gut.
###end article-title 93
###begin article-title 94
###xml 32 37 <span type="species:ncbi:9606">human</span>
Host-bacterial mutualism in the human intestine.
###end article-title 94
###begin article-title 95
Genetics of Crohn disease, an archetypal inflammatory barrier disease.
###end article-title 95
###begin article-title 96
Extreme heterogeneity in CARD15 and DLG5 Crohn disease-associated polymorphisms between German and Norwegian populations.
###end article-title 96
###begin article-title 97
Association of DLG5 and inflammatory bowel disease across populations.
###end article-title 97
###begin article-title 98
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes.
###end article-title 98
###begin article-title 99
###xml 85 90 <span type="species:ncbi:9606">human</span>
Paneth cell antimicrobial peptides: Topographical distribution and quantification in human gastrointestinal tissues.
###end article-title 99
###begin article-title 100
###xml 37 42 <span type="species:ncbi:9606">human</span>
In vivo gene expression profiling of human intestinal epithelial cells: analysis by laser microdissection of formalin fixed tissues.
###end article-title 100
###begin p 101
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: MJK, JB, EFS and JW have a pending patent application regarding TCF-4 SNP detection.
###end p 101
###begin p 102
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
###xml 330 337 <span type="species:ncbi:9606">patient</span>
Funding: JW is an Emmy Noether scholar of Deutsche Forschungsgemeinschaft (DFG) who supported this work (WE 436/1-1). This work was also supported by the Robert Bosch Foundation (Stuttgart, Germany), the Ernst Jung Foundation (Hamburg, Germany), the National Institute of Health (AI32738 and AI50843), as well as the DCCV (German patient organization of Crohn's disease and ulcerative colitis). S. V and P. R. are supported by the Funds for Scientific Research (FWO), Flandres, Belgium.
###end p 102

